These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 35613493

  • 21. Imipenem-Relebactam Susceptibility and Genotypic Characteristics of Carbapenem-Resistant Enterobacterales Identified during Population-Based Surveillance.
    Horwich-Scholefield S, Lloyd T, Varghese V, Yette E, Huang S, Pandori M.
    Antimicrob Agents Chemother; 2021 Oct 18; 65(11):e0228820. PubMed ID: 34370572
    [Abstract] [Full Text] [Related]

  • 22. Investigation of in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against carbapenem resistant Klebsiella pneumoniae strains.
    Adaleti R, Nakipoğlu Y, Çalık Ş, Arıcı N, Kansak N, Şenbayrak S, Aksaray S.
    Acta Microbiol Immunol Hung; 2023 Jun 16; 70(2):155-160. PubMed ID: 37133999
    [Abstract] [Full Text] [Related]

  • 23. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.
    Poirel L, Kieffer N, Nordmann P.
    J Antimicrob Chemother; 2016 Jan 16; 71(1):156-61. PubMed ID: 26416781
    [Abstract] [Full Text] [Related]

  • 24. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.
    Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Sahm DF.
    J Med Microbiol; 2020 Feb 16; 69(2):207-217. PubMed ID: 31976856
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A, Akyön Y, Gür D, Karatuna O, Öğünç D, Özhak Baysan B, Çöplü N, Çağatay M, Kılıç A, Baysallar M, Bakıcı Z, Çelik C, Gülay Z, Aydemir Ş, Tünger A, Kılıç H, Erçal BD, Aşçı Toraman Z, Zer Y, Büyüktaş A, Ay S, Aktaş Z, Kayacan Ç, Bayramoğlu G, Aydın F, Dündar D, Hasdemir U, Ayaş R, Yanık K, Günaydın M, Güdücüoğlu H, Parlak M.
    Mikrobiyol Bul; 2016 Jan 16; 50(1):21-33. PubMed ID: 27058326
    [Abstract] [Full Text] [Related]

  • 31. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z, Kayacan C, Oncul O.
    Int J Antimicrob Agents; 2012 Jan 16; 39(1):86-9. PubMed ID: 22041508
    [Abstract] [Full Text] [Related]

  • 32. Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates.
    Abbas HA, Kadry AA, Shaker GH, Goda RM.
    Microb Pathog; 2019 Jul 16; 132():266-274. PubMed ID: 31096002
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
    Liang R, Wang D, Hu M, Gu Y, Wang M, Hu D, Zhu M, Wang M.
    J Antibiot (Tokyo); 2023 Sep 16; 76(9):540-547. PubMed ID: 37217796
    [Abstract] [Full Text] [Related]

  • 35. In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.
    Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF.
    Antimicrob Agents Chemother; 2018 Jul 16; 62(7):. PubMed ID: 29760135
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa.
    López-Pérez M, Haro-Moreno JM, Molina-Pardines C, Ventero MP, Rodríguez JC.
    mSphere; 2021 Dec 22; 6(6):e0083621. PubMed ID: 34817240
    [Abstract] [Full Text] [Related]

  • 39. In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan.
    Kurihara D, Matsumoto S, Kishi N, Ishii Y, Mori M.
    Microbiol Spectr; 2022 Apr 27; 10(2):e0223521. PubMed ID: 35416695
    [Abstract] [Full Text] [Related]

  • 40. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 27; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.